EZH2 inhibitor, Tazemetostat, alone, and in conjunction with other therapies, is currently in clinical trials for treating pediatric glioma with EZH2, SMARCB1, or SMARCA4 mutations (ClinicalTrials.gov IDs NCT03213665, NCT03155620). The gene discussed is EZH2; the disease is central nervous system cancer.